Jemma Hopewell

Home / Investigators  / Jemma Hopewell

Jemma Hopewell

Associate Professor & Senior Scientist, Genetic Epidemiology and Clinical Trials, University of Oxford

Email: jemma.hopewell@ndph.ox.ac.uk
Phone: +44 (0)1865 743661

Dr. Jemma Hopewell leads a team of genetic epidemiologists, clinical fellows, medical statisticians and bioinformaticians in a programme of research focusing on the use of genetic and clinical trial-based studies to investigate the causes and treatments for cardiovascular disease and arrhythmias. She has particular interests in determining predictors of patient response to therapy, using genetics to improve our understanding of drug targets and disease mechanisms, and genomic characterisation of vascular disease and its risk factors, particularly Lp(a). Jemma leads and collaborates on numerous projects involving CTSU’s vascular mega-trials (e.g. HPS, SEARCH, THRIVE, REVEAL), large-scale studies and biobanks (e.g. PROCARDIS, UK Biobank), and international consortia (e.g. METASTROKE, CARDIoGRAMplusC4D, GoLEAD, CATCH-ME). She is a member of the Lp(a) Foundation Scientific Advisory Board, of various clinical trial and genetic study Steering and Analysis Committees, and is currently the Chair of METASTROKE (a collaboration of the International Stroke Genetics Consortium), as well as co-ordinating the MSc in Global Health Science Genetic Epidemiology module.

Recent Publications

  • Gajendragadkar, PR, Von Ende, A, Ibrahim, M, Valdes-Marquez, E, Camm, CF, Murgia, F et al.. Assessment of the causal relevance of ECG parameters for risk of atrial fibrillation: A mendelian randomisation study. PLoS Med. 2021;18 (5):e1003572. doi: 10.1371/journal.pmed.1003572. PubMed PMID:33983917 PubMed Central PMC8118296.
  • Dambha-Miller, H, Griffin, SJ, Young, D, Watkinson, P, Tan, PS, Clift, AK et al.. The Use of Primary Care Big Data in Understanding the Pharmacoepidemiology of COVID-19: A Consensus Statement From the COVID-19 Primary Care Database Consortium. Ann Fam Med. ;19 (2):135-140. doi: 10.1370/afm.2658. PubMed PMID:33685875 PubMed Central PMC7939714.
  • Hopewell, JC, Clarke, R, Watkins, H. Lp(a) (Lipoprotein[a]), an Exemplar for Precision Medicine: Insights From UK Biobank. Arterioscler Thromb Vasc Biol. 2021;41 (1):475-477. doi: 10.1161/ATVBAHA.120.315549. PubMed PMID:33356370 .
  • Hopewell, JC, Offer, A, Haynes, R, Bowman, L, Li, J, Chen, F et al.. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. Eur Heart J. 2020;41 (35):3336-3342. doi: 10.1093/eurheartj/ehaa574. PubMed PMID:32702748 PubMed Central PMC7544537.
  • Oster, J, Hopewell, JC, Ziberna, K, Wijesurendra, R, Camm, CF, Casadei, B et al.. Identification of patients with atrial fibrillation: a big data exploratory analysis of the UK Biobank. Physiol Meas. 2020;41 (2):025001. doi: 10.1088/1361-6579/ab6f9a. PubMed PMID:31978903 .
  • Georgakis, MK, Malik, R, Anderson, CD, Parhofer, KG, Hopewell, JC, Dichgans, M et al.. Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol. Brain. 2020;143 (2):597-610. doi: 10.1093/brain/awz413. PubMed PMID:31968102 PubMed Central PMC7009571.
  • Schmidt, AF, Holmes, MV, Preiss, D, Swerdlow, DI, Denaxas, S, Fatemifar, G et al.. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovasc Disord. 2019;19 (1):240. doi: 10.1186/s12872-019-1187-z. PubMed PMID:31664920 PubMed Central PMC6820948.
  • Doehner, W, Mazighi, M, Hofmann, BM, Lautsch, D, Hindricks, G, Bohula, EA et al.. Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. Eur J Prev Cardiol. 2020;27 (7):682-692. doi: 10.1177/2047487319873460. PubMed PMID:31569966 PubMed Central PMC7227126.
  • Oikonomou, EK, Williams, MC, Kotanidis, CP, Desai, MY, Marwan, M, Antonopoulos, AS et al.. A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CT angiography. Eur Heart J. 2019;40 (43):3529-3543. doi: 10.1093/eurheartj/ehz592. PubMed PMID:31504423 PubMed Central PMC6855141.
  • Haynes, R, Valdes-Marquez, E, Hopewell, JC, Chen, F, Li, J, Parish, S et al.. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. Clin Ther. 2019;41 (9):1767-1777. doi: 10.1016/j.clinthera.2019.06.012. PubMed PMID:31447131 .
Search PubMed